Mestinon is available in the following forms: syrup containing 60
mg pyridostigmine bromide per teaspoonful in vehicle containing
5% alcohol, glycerin, lactic acid, sodium benzoate, sorbitol,
sucrose, FD&C Red No 40, FD&C Blue No 1, flavours and water.
Tablets containing 60 mg pyridostigmine bromide; each tablet also
contains lactose, silicon dioxide and stearic acid. Timespan
tablets containing 180 mg pyridostigmine bromide; each tablet
contains carnauba wax, corn derived proteins, magnesium stearate,
silica gel and tribasic calcium phosphate.
Actions: Mestinon inhibits the destruction of acetylcholine by
cholinesterase and thereby permits freer transmission of nerve
impulses across the neuromuscular junction. Pyridostigmine is an
analog of neostigmine (Prostigmin), but differs from it in
certain clinically significant respects; for example,
pyridostigmine is characterized by a longer duration of action
and fewer gastrointestinal side effects.
Indication: Mestinon is useful in the treatment of myasthenia
gravis.
Contraindications: Mestinon is contraindicated in mechanical
intestinal or urinary obstruction, and particular caution should
be used in it's administration to patients with bronchial asthma.
Care should be observed in the use of atropine for counteracting
side effects, as discussed below.
Warnings: Although failure of patients to show clinical
improvement may reflect underdosage, it can also be indicative of
overdosage. As is true of all cholinergic drugs, overdosage of
Mestinon may result in cholinergic crisis, a state characterized
by increasing muscle weakness which, through involvement of the
muscles of respiration, may lead to death. Myasthenic crisis due
to an increase in the severity of the disease is also accompanied
by extreme muscle weakness, and thus may be difficult to
distinguish from cholinergic crisis on a symptomatic basis. Such
differentiation is extremely important, since increases in doses
of Mestinon or other drugs of this class in the presence of
cholinergic crisis or of a refractory or "intensive" state could
have grave consequences. Osserman and Gerkins indicate that the
differential diagnosis of the two types of crisis may require the
use of Tensilon (edrophonium chloride) as well as clinical
judgement. The treatment of the two conditions obviously differs
radically. Whereas the presence of myasthenic crisis suggests the
need for more intensive anticholinesterase therapy, the diagnosis
of cholinergic crisis, according to Osserman and Gerkins, calls
for the prompt withdrawal of all drugs of this type. The
immediate use of atropine in cholinergic crisis is also
recommended.
Atropine may also be used to abolish or obtund
gastrointestinal side effects or other muscarinic reactions; but
such use, by masking signs of overdosage, can lead to inadvertent
induction of cholinergic crisis.
For detailed information on the management of patients with
myasthenia gravis, the physician is referred to one of the
excellent reviews such as those by Osserman and Gerkins, Grob or
Schwab.
Usage in pregnancy: The safety of Mestinon during pregnancy or
lactation in humans has not been established. Therefore, use of
Mestinon in women who may become pregnant requires weighing the
drugs potential benefits against its possible hazards to mother
and child.
Adverse reactions: The side effects of Mestinon are most commonly
related to overdosage and generally are of two varieties,
muscarinic and nicotinic. Among those in the former group are
nausea, vomiting, diarrhoea, abdominal cramps, increased
peristalsis, increased salivation, increased bronchial
secretions, miosis and diaphoresis. Nicotinic side effects are
comprised chiefly of muscle cramps, fasciculation and weakness.
Muscarinic side effects can usually be counteracted by atropine,
but for reasons shown in the preceding section the expedient is
not without danger. As with any compound containing the bromide
radical, a skin rash may be seen in an occasional patient. Such
reactions usually subside promptly upon discontinuance of the
medication.
Dosage and administration: Mestinon is available in three dosage
forms:
Syrup-raspberry flavoured - containing 60 mg pyridostigmine
bromide per teaspoonful (5 mL). This form permits accurate dosage
adjustment for children and "brittle" myasthenic patients who
require fractions of 60 mg doses. It is more easily swallowed,
especially in the morning, by patients with bulbar involvement.
Conventional tablets - each containing 60 mg pyridostigmine
bromide.
Timespan tablets - each containing 180 mg of pyridostigmine
bromide. This form provides uniformly slow release, hence
prolonged duration of drug action; it facilitates control of
myasthenic symptoms with fewer individual doses daily. The
immediate effect of a 180 mg Timespan tablet is about equal to
that of a 60 mg conventional tablet; however, it's duration of
effectiveness, although varying in individual patients, averages
21/2 times that of a 60 mg dose.
Top of Page | Current Section Index |
---|